| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Novavax Inc (NVAX) has 8 insiders with recent SEC Form 4 filings, including 2 buys and 0 sells. NVAX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 264.1K | $2.42M | - | |
| CFO | 145.1K | $1.33M | - | |
| VP | 112.7K | $1.03M | - | |
| VP | 34.9K | $320.0K | - | |
| Dir | 28.5K | $261.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2015 | Phillips Barclay A | SVP, Chief Financial Officer | Buy | 8,388 | $2.28 | $19,124.64 | +29.3% | |
| Jan 31, 2015 | Erck Stanley C86 | CEO And President | Buy | 6,122 | $2.28 | $13,958.16 | +6.7% |